brazikumab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
brazikumab

GtoPdb Ligand ID: 9293

Synonyms: AMG 139 | AMG-139 | MEDI2070

Compound class: Antibody

Comment: Brazikumab (AMG 139, MEDI2070) is a fully human anti-IL23A monoclonal antibody in clinical development for autoimmune indications.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide anaylsis reveals identical matches with peptides claimed in patent WO2011056600 [3].

Bioactivity Comments
It is unclear which anti-IL-23 antibody in patent WO2011056600 is AMG 139, although antibodies B and E were crystalised to produce X-ray structures, suggesting these were preferred agents [3]. In binding affinity experiments using recombinant human IL-23, all of the chosen antibodies produced equilibrium dissociation constant (K_D) values <4pM [3].

Bioactivity Comments

It is unclear which anti-IL-23 antibody in patent WO2011056600 is AMG 139, although antibodies B and E were crystalised to produce X-ray structures, suggesting these were preferred agents [3]. In binding affinity experiments using recombinant human IL-23, all of the chosen antibodies produced equilibrium dissociation constant (K_D) values <4pM [3].

Selectivity at ligand targets

Key to terms and symbols

Click column headers to sort

Target			Sp.	Type	Action	Value	Parameter	Concentration range (M)	Reference
IL-23A			Hs	Antibody	Binding	>11.4	pK_d	-	3
⤷	pK_d >11.4 (K_d <4x10^-12 M) [3] Description: Measured using KinExA technology (a kinetic exclusion assay)